Ardent Health, Inc. (ARDT): what the price assumes

boothcheck covers Ardent Health, Inc. (ARDT) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-07-25.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/ARDT

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 5.9% sits below it).

How unusual the bet is: n/a

Valuation X-Ray

The price is supported by earnings-power and growth-DCF value, while asset-based/relative-multiple land below the price. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Earnings, Growth Families that call it expensive: Asset, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.1%); the inversion above states its own rate.

Per-Model Detail (n=12)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Commercial and other managed-care plans are the largest revenue line at 44% of the total, ahead of Medicare at 39% and Medicaid at 10%, which is the payer mix a hospital operator wants and not the one most people assume it has.
• The competitive threat is structural rather than commercial: the FY2025 10-K notes that rival hospitals owned by governments or not-for-profits "can finance capital expenditures and operations on a tax-exempt basis", a cost-of-capital advantage no operating improvement can close.
• Volume is the number to watch, because total admissions fell 1.1% in the first quarter of 2026 on severe weather and a light respiratory season even as surgeries grew.

Bull Case

The counterintuitive fact sits in the revenue mix. Most investors assume a mid-market hospital chain lives on government reimbursement, and here the largest single payer category is commercial and other managed care at 44% of revenue, with Medicare at 39% and Medicaid at 10%. Commercial plans pay materially better rates than either government program. That mix is the difference between a hospital system that grinds and one that compounds, and it is the first thing a reader should register about Ardent Health.

The second is how the hospitals are owned. Nine of them carry significant minority stakes held by third parties, in many cases not-for-profit health systems, and the 10-K notes that "our JV agreements are structured to comply with current revenue rulings published by the U.S. Internal Revenue Service". Joint ventures with academic and not-for-profit partners are usually read as a governance complication. Read them instead as market access: the partner brings the referral network and the local reputation, Ardent brings the operating platform and the capital, and the combination is why the company states it holds "a leading position in a majority of our markets". Buying that position outright in a mid-sized city is not usually for sale at any price.

The operating story underneath is about cost per case rather than volume heroics. Contract labor, the line that broke hospital economics across the industry, fell by more than 40% to 15 million dollars in the first quarter of 2026, and salaries and benefits per adjusted admission declined 1.4%. The company's IMPACT program is targeted at 55 million dollars of savings for 2026. Against trailing revenue of roughly 6.4 billion dollars and a 4.2% trailing operating margin, cost recovery of that size is not a rounding item. It is most of the gap between this margin and a respectable one.

There is also a clinical program that shows what the operating platform actually does. The 10-K reports that in 2025 its wearable monitoring technology "was utilized by more than 77,000 patients" and that early implementation showed a 15% reduction in mortality in monitored units alongside a reduction in length of stay of roughly a third of a day. Shorter stays free beds, and in a fixed-plant business a freed bed is incremental revenue with almost no incremental cost. Hospital technology usually gets described in terms of what it might do. This one has a patient count attached.

Bear Case

The most dangerous competitor does not have shareholders. The 10-K is blunt about it: some competing hospitals are owned by governmental agencies or not-for-profit corporations supported by endowments and charitable contributions, and they "can finance capital expenditures and operations on a tax-exempt basis". In a business where the fight is over which building gets the new imaging suite and which one recruits the orthopedic group, a competitor funding that building at tax-exempt rates wins ties permanently. No amount of purchasing discipline offsets a structurally cheaper cost of capital.

The second pressure comes from the other side of the ledger. Insurers are consolidating, and the filing states that consolidation "may result in insurers having increased negotiating leverage and competitive advantages, such as greater access to performance and pricing data", with private payors continuing to demand discounted fee structures and to deploy narrow and tiered networks. The 44% commercial share that anchors the bull case is exactly the revenue an insurer with more leverage would target first. Favorable payer mix is not a moat if the counterparty gets bigger every year.

Then there is where the profitable work is migrating. Surgery Partners runs freestanding surgical facilities and turns an 11.8% operating margin on 3.3 billion dollars of revenue; SGRY does that without carrying an emergency department, an intensive care unit, or an obstetrics ward. Ardent Health earns 4.2%. The outpatient cases that move to an ambulatory setting are precisely the scheduled, insured, high-contribution procedures, and what stays behind is the fixed-cost inpatient plant and the unscheduled work. Total admissions already fell 1.1% in the first quarter of 2026 while surgeries grew 1.2%. One quarter of weather-affected data proves nothing on its own. The direction is the one the structural argument predicts.

Scale is the other thing missing. THC earns an 18.0% operating margin on 21.5 billion dollars of revenue and UHS earns 11.5% on 17.8 billion dollars; both negotiate with the same national insurers from a much larger base. Ardent Health operates roughly 6.4 billion dollars of revenue across a smaller footprint, and the margin difference is not primarily an execution gap.

The balance sheet does not create the risk but it does transmit it. Gross borrowings of 1,140.5 million dollars against 609.7 million of liquid assets leave net funded borrowings of 530.8 million, which is 1.98 times operating profit; the lease-inclusive measure used elsewhere in the capital structure is roughly three times that funded figure, and for a hospital operator that rents much of its plant the lease-inclusive number is the honest one. Meanwhile the share count has grown about 4.3% a year since mid-2023. A business with thin operating margins, a rising share count, and rent obligations that behave like debt has less room to absorb a bad reimbursement year than the headline leverage suggests.

Valuation

Book value is where this one starts, because the quote is barely above it. The balance sheet reports 9.43 dollars of book value per share and the shares change hands at 10.61. Return on equity runs at 10.0% against a required return near 9.3%, which is to say the company earns a whisker more than its cost of equity and the market has priced it accordingly. That is an unusually literal relationship for an equity, and it explains why the asset-value methods land almost exactly where the shares trade.

What the quote asks of the operating business is similarly undemanding. The whole enterprise is priced at 12.1 times its annual operating profit, low enough that the shares sit below what even a shrinking profit stream would warrant. That is a boundary rather than a forecast: the market is not underwriting growth here, and it is not underwriting stability either.

The methods split along a clean line. Asset-value and earnings-power approaches both land essentially at the current quote, one a fraction above and one a fraction below. Peer-multiple and cash-flow approaches land well above it. That is the signature of a company the market values on what it owns and currently earns rather than on what it might earn later, and it is a very different reading from a stock priced on a growth story. The cash-flow methods get their distance by projecting the recent revenue trajectory forward at the historical pace, which is exactly the assumption an operator with declining admissions has to defend.

The peer cohort explains part of the discount and none of the rest. THC turns an 18.0% operating margin on 21.5 billion dollars of revenue, UHS 11.5% on 17.8 billion, ENSG 8.5% on 5.3 billion, and SEM 5.8% on 5.5 billion. Ardent Health earns 4.2%. Against the scaled acute-care operators the margin gap is wide; against SEM, which runs a similarly capital-heavy service mix, the gap narrows to under two points. Where a reader places this company in that range determines most of the valuation question, and the peer-multiple methods place it near the top, which is generous.

Solvency does the bounding work. Gross borrowings run 1,140.5 million dollars against liquid assets of 609.7 million, leaving 530.8 million net on the funded build-up, or 1.98 times operating profit. The company is not burning cash. The two facts that qualify the comfort are the lease-inclusive obligation, which is several times the funded figure and behaves like debt for an operator that rents much of its plant, and a share count rising roughly 4.3% a year since mid-2023. Neither is alarming on its own. Both mean the equity's claim on the business has been getting slightly smaller while the fixed obligations have not.

Catalysts

The first quarter of 2026 gave a clean read on the cost side and a murkier one on volume. Revenue rose 7% to 1.6 billion dollars, salaries and benefits improved 260 basis points as a share of revenue, and contract labor fell by more than 40% to 15 million dollars. Total surgeries grew 1.2% with outpatient surgeries up 1.7%, while total admissions declined 1.1%, which management attributed to severe weather and a lighter respiratory season.

Guidance was reaffirmed rather than raised. Management held full-year 2026 revenue at 6.4 to 6.7 billion dollars and adjusted admissions growth at 1.5% to 2.5%, and confirmed the IMPACT cost program at 55 million dollars of savings for the year. Reaffirming after a quarter with a soft admissions line is the more informative choice: it says management reads the volume shortfall as weather rather than trend. The second and third quarters are where that reading gets tested, because the respiratory-season excuse expires with the season.

The regulatory item running underneath all of it is Medicaid supplemental payment programs. These are designed with input from and subject to periodic renewal by the Centers for Medicare and Medicaid Services, funded by a mix of state and federal money and in some cases by fees or taxes levied on the providers themselves. The 10-K notes that increased provider assessments tied to those programs raised total operating expenses as a share of revenue in 2025. Programs that require renewal are programs that can change, and for a company earning a 4.2% operating margin the renewal calendar carries more weight than the volume calendar.

Peer Cohorts (Per Segment, With Filing Citations)

Healthcare Services (single segment) (reported)

• SGRY (Surgery Partners, Inc.)
• FY2025 10-K: …to contracts with patients in which the performance obligations are to provide health care services. The Company recognizes revenues in the period in which its obligations to provide health care services are satisfied and reports the amount that reflects the consideration the Company expects to be entitled to…
• FY2025 10-K: …We provide each of our surgical facilities with a full range of financial, marketing and operating services. For example, our regional managed care directors assist the local management team at each of our surgical facilities in developing relationships with private insurance payors and negotiating private insurance…
• UHS (UNIVERSAL HEALTH SERVICES, INC.)
• FY2025 10-K: …to certain facilities previously included in our Behavioral Health Care Services' results have been reclassified into our Acute Care Hospital Services' results as of May 1, 2024 to conform with current year presentation. 2025 Acute Care Hospital Services Behavioral Health Care Services (c) Total (amounts in…
• FY2025 10-K: …services during 2025 and 2024. These amounts include: (i) our behavioral health care results on a Same Facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other…
• THC (TENET HEALTHCARE CORP)
• FY2025 10-K: …pre‑certification, registration and check‑in services; and financial counseling services, including reviews of eligibility for government healthcare or financial assistance programs, for both insured and uninsured patients, as well as qualified health plan coverage; (2) clinical revenue integrity solutions,…
• FY2025 10-K: …obligations: • revenue cycle management services; • value‑based care services; • patient communication and engagement services; • consulting services; and • other client‑defined projects. Our contracts generally consist of fixed‑price, volume‑based or contingency‑based fees. Long‑term contracts typically provide for…
• MD (Pediatrix Medical Group, Inc.)
• FY2025 10-K: Statements of Income and Comprehensive Income. See the Consolidated Financial Statements for the Company's segment revenue, significant segment expenses, other segment expenses and net income. Revenue Recognition Patient service revenue is recognized at the time services are provided by the Company's affiliated…
• FY2025 10-K: …professional services provided by our affiliated physicians to patients based upon rates for specific services provided, principally from third-party payors. Our billed charges are substantially the same for all parties in a particular geographic area, regardless of the party responsible for paying the bill for our…
• SEM (SELECT MEDICAL HOLDINGS CORP)
• FY2025 10-K: …methods. These programs are monitored quarterly and estimates are revised as necessary to take into account additional information. The Company also records insurance proceeds receivable for liabilities which exceed the Company's deductibles and self-insured retention limits and are recoverable through its insurance…
• FY2025 10-K: …it provides, which principally consist of management and employee leasing services provided under contractual arrangements with related parties affiliated with the Company and non-affiliated healthcare institutions. The Company accounts for management and employee leasing services as single performance obligations…
• NHC (NATIONAL HEALTHCARE CORP)
• FY2025 10-K: …competitive with other market rates. ● Medical Specialty Units. All our skilled nursing facilities participate in the Medicare program, and we have expanded our range of offerings by the creation of facility-specific medical specialty units such as our memory care units and sub-acute nursing units. Our trained staff…
• FY2025 10-K: …Drug Plans (PDPs) electronically and directly for inpatients who have selected a PDP. ● Institutional Special Needs Plan ( " I-SNP " ). Our I-SNP, which is called NHC Advantage, is a managed care insurance company that restricts enrollment to Medicare Advantage eligible individuals who, for 90 days or longer, have…
• ENSG (ENSIGN GROUP, INC)
• FY2025 10-K: …intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable. Service Revenue Recognition - The Company…
• FY2025 10-K: $ 272,762 (1) Skilled services service revenue does not include intercompany service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in…
• PACS (PACS Group, Inc.)
• FY2025 10-K: COMBINED/CONSOLIDATED FINANCIAL STATEMENTS (dollars in thousands, except for share and per share values) Patient and Resident Service Revenue The Company's patient and resident service revenue is derived primarily from the Company's applicable subsidiaries providing healthcare services to their respective patients and…
• FY2025 10-K: …industry in the markets in which we operate were to occur, it could reduce the occupancy rates of existing facilities and, in some cases, might reduce the private rates that we charge for our services. If we fail to attract patients and residents and to compete effectively with other healthcare providers, our revenue…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.